

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Randomized double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy - study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050264
Article Type:	Protocol
Date Submitted by the Author:	16-Feb-2021
Complete List of Authors:	Siltari, Aino; Tampere University, Faculty of Medicine and Health Technology; University of Helsinki, Faculty of Medicine, Pharmacology Riikonen, Jarno; Tampere University Hospital, Department of Urology Koskimäki, Juha; Tampere University Hospital, Department of Urology Pakarainen, Tomi; Tampere University Hospital, Department of Urology Ettala, Otto; University of Turku Boström, Peter; University of Turku Seikkula, Heikki; Central Finland Central Hospital Kotsar, Andres; Tartu University Hospital Tammela, Teuvo; University of Tampere Helminen, Mika; Tampere University, Health Sciences Lehtimäki, Terho; Tampere University, Department of Clinical Chemistry Fode, Mikkel; Herlev Hospital Østergren, Peter; Herlev and Gentofte University Hospital, Department of Urology Borre, Michael; Aarhus Universitetshospital, Department of Urology Rannikko, Antti; Helsinki University and Helsinki University Hospital, Department of Urology Marttila, Timo; Seinäjoki Central Hospital, Department of Urology Salonen, Arto; Kuopio University Hospital Ronkainen, Hanna; Oulu University Hospital Murtola, Teemu J ; Tampere University Hospital, Department of Urology
Keywords:	Prostate disease < UROLOGY, Clinical trials < THERAPEUTICS, Urological tumours < ONCOLOGY

SCHOLARONE™
Manuscripts

Randomized double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy - study protocol

Aino Siltari¹, Jarno Riikonen², Juha Koskimäki², Tomi Pakarainen², Otto Ettala³, Peter Boström³, Heikki Seikkula⁴, Andres Kotsar⁵, Teuvo LJ Tammela^{1,2}, Mika Helminen^{7,8}, Terho Lehtimäki^{1,9}, Mikkel Fode¹⁰, Peter Østergren¹⁰, Michael Borre¹¹, Antti Rannikko¹², Timo Marttila¹³, Arto Salonen¹⁴, Hanna Ronkainen¹⁵, Teemu J Murtola^{1,2*}

¹Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland, ²TAYS Cancer Center, Department of Urology, Tampere, Finland, ³Turku University Hospital and University of Turku, Turku, Finland, ⁴Central Finland Central Hospital, Jyväskylä, Finland, ⁵Tartu University Hospital, Department of Urology, Tartu, Estonia, ⁶Fimlab laboratories, Department of Pathology, Tampere, Finland, ⁷Tampere University Hospital, Research Services, Tampere, Finland, ⁸Tampere University, Faculty of Social Sciences, Health Sciences, Tampere Finland, ⁹Fimlab Laboratories, Department of Clinical Chemistry, Tampere, Finland, ¹⁰Department of Urology, Herlev and Gentofte Hospital, Denmark, ¹¹Aarhus University Hospital, Department of Urology, Aarhus, Denmark, ¹²Helsinki University and Helsinki University Hospital, Department of Urology, Helsinki, Finland ¹³Seinäjoki Central Hospital, Department of Urology, Seinäjoki, Finland, ¹⁴Kuopio University Hospital, Department of Urology, Kuopio, Finland, ¹⁵Oulu University Hospital, Department of Urology, Oulu, Finland

*corresponding author: Teemu J Murtola, Department of Urology, Tampere University Hospital, PL 2000, 33521 Tampere, Finland, teemu.murtola@tuni.fi, telephone: +358 (0) 294 52 11.

Keywords: Prostate cancer; castration-resistant prostate cancer; androgen deprivation therapy; atorvastatin; randomized clinical trial

Word count: 3604 (excluding title page, references, figures, and tables)

Abstract

Introduction

Blood cholesterol is likely a risk factor for prostate cancer prognosis and use of statins is associated with lowered risk of prostate cancer recurrence and progression. Furthermore, use of statins has been associated with prolonged time before development of castration resistance (CR) during androgen deprivation therapy (ADT) for prostate cancer. However, the efficacy of statins on delaying castration-resistance has not been tested in a randomized placebo-controlled setting.

This study aims to test statins' efficacy compared to placebo in delaying development of CR during ADT treatment for primary metastatic or recurrent prostate cancer in a randomized, placebo-controlled, double-blind clinical trial. Secondary aim is to explore effect of statin intervention on prostate cancer mortality and lipid metabolism during ADT.

Methods and analysis

A total of 400 men with *de novo* metastatic prostate cancer or recurrent disease after primary treatment and starting ADT will be recruited and randomized 1:1 to use daily 80 mg of atorvastatin or placebo. Patients are followed until disease recurrence or death. Primary outcome is time to formation of CR after initiation of ADT. Serum lipid levels are analyzed to test whether changes in serum cholesterol parameters during ADT predict length of treatment response. Furthermore, the trial will compare quality of life, cardiovascular morbidity, changes in blood glucose and circulating cell-free DNA, and urine lipidome during trial.

Ethics and dissemination

This study is approved by the Regional ethics committees of the Pirkanmaa Hospital District, Science center, Tampere, Finland (R18065M) and Tartu University Hospital, Tartu, Estonia (319/T-6). All participants read and sign informed consent form before study entry. Clinicaltrial.gov: NCT04026230, Eudra-CT: 2016-004774-17, protocol code: ESTO2, protocol date September 10th 2020 and version 6.

Keywords: Prostate cancer; castration-resistant prostate cancer; androgen deprivation therapy; atorvastatin; randomized clinical trial

Strengths and limitations of this study

- First randomized placebo-controlled phase 3 clinical study on effects of atorvastatin on prostate cancer progression during ADT treatment.
- Clarifies the role of lipid metabolism in prostate cancer progression
- Investigates whether management of most severe cases of prostate cancer could be improved using cheap well-tolerated drug with established cardiovascular benefits
- Investigates the effects of atorvastatin treatment on glucose tolerance, mortality, and quality of life
- As a limiting factor, only minority of prostate cancer cases are advanced and large proportion of potential participants are ineligible due to using statins already. Thus, study enrolment will take several years

Introduction

Prostate cancer (PCa) is the most common cancer in Finnish men and a major public health burden causing annually around 900 cancer deaths in Finland and the yearly costs caused by the disease are estimated to reach 180 million euros.¹⁻² However, not all prostatic malignancies are lethal; only 10-20% of tumors advance to metastases and eventually into a fatal stage. Advanced PCa is treated by androgen deprivation therapy (ADT). Eventually, however, PCa progress despite the ADT treatment and forms state called castration resistance. Thus, castration resistance is clinically defined as a moment when prostate cancer no longer responds to ADT treatment. Median time to castration resistance is 12-15 months and 45 months to death in patients who have started ADT for metastatic prostate cancer.³⁻⁷ In men who start ADT for disease recurrence after primary treatment, median failure-free survival time is 33 months and 70 months to death.³

Blood cholesterol is likely a risk factor for prostate cancer prognosis; risk of disease recurrence after primary treatment is significantly elevated in men with hypercholesterolemia.⁸ Importance of cholesterol is also supported by studies demonstrating effects of cholesterol on prostate cancer cell growth.^{9,10} Furthermore, upregulation of intracellular lipid production and ensuing lipid accumulation is essential in surviving hypoxic tumor microenvironment.¹¹ In prostate cancer cells it also assists in evading host-tumor immune response.¹² Also, upregulation of intracellular cholesterol production appears to be central for development of castration resistance.¹³

1
2
3 Lipid metabolism is emerging as a new risk factor for prostate cancer progression. The role of
4 cholesterol is important in development of castration resistance, and inhibition of intracellular lipid
5 production interferes with androgen receptor (AR) signaling essential for prostate cancer
6 progression¹³⁻¹⁵. Cholesterol is precursor for intracellular androgen production, a central mechanism
7 for prostate cancer cells to overcome ADT.^{13,15} A recent study suggests that some of the serum basic
8 lipid parameters may have increased association with development of castration resistance and
9 metastasis especially in statin-naïve patients.¹⁶ Clarification of the role of lipid metabolism during
10 ADT will likely provide new tools for control of disease progression and prostate cancer treatment.
11
12

13
14
15
16
17
18 Use of cholesterol-lowering statin drugs is associated with lowered risk of prostate cancer recurrence
19 and progression; risk of prostate cancer death is reduced by 30% compared to the non-users.^{14,17,18}
20 The anticancer effect may be specifically against progression of the disease and the mechanisms
21 driving it.¹⁹ Statins inhibit the cholesterol-synthesizing mevalonate pathway, which is active in
22 prostate cancer cells.^{10,20} Besides cholesterol, this pathway produces also isoprenoid proteins which
23 are critical for regulation of cell growth and other central cellular control processes.²⁰ Furthermore,
24 steroid hormones such as testosterone are metabolized from cholesterol, thus statins appear to target
25 androgen metabolism, another crucial pathway for prostate cancer growth.^{21,22}
26
27
28
29
30
31

32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Statin use has been reported to prolong efficacy of ADT in prostate cancer as it has been reported to
prolong the efficacy of ADT for 8-10 months.^{23,24} Furthermore, statins have been linked to a
prolonged response to androgen-signaling targeted drugs abiraterone and enzalutamide used in
management of castration-resistant disease.^{25,26}

41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Statin use has not been found to affect prostate cancer mortality in trials testing their efficacy in
secondary prevention of cardiovascular disease.²⁷ However, in these trials cancer was often an
exclusion criterion. On the other hand, it may be that statin treatment has more impact on hormone-
dependent cancers which are underrepresented in these studies. In a randomized clinical trial focusing
on prostate cancer patients 80 mg of atorvastatin has been found to reduce tumor proliferation activity
compared to placebo after minimum exposure of 21 days.²⁸ Similar results were seen after treatment
with fluvastatin, although in a non-randomized and uncontrolled setting.²⁹ Nevertheless, clinical
efficacy of statins in preventing progression of prostate cancer has not been tested in a randomized
placebo-controlled setting. Also, a recent post-hoc study of randomized clinical trial concluded that
statin use was associated with decreased overall and PCa-specific mortality in men with ADT.³⁰
Therefore, it is important to do a trial testing effects of statins specifically in prostate cancer patients.

Study objective

Primary objective for this phase III randomized double-blind placebo-controlled trial is to explore whether intervention with atorvastatin delays prostate cancer progression i.e. development of castration resistance compared to placebo during androgen deprivation therapy (ADT) for metastatic or recurrent prostate cancer. Secondary objectives include exploring whether atorvastatin lowers prostate cancer-specific or overall mortality compared to placebo, and to demonstrate whether changes in serum lipid parameters predict disease recurrence and occurrence of adverse tumor genomic traits predicting castration resistance among prostate cancer patients during ADT.

Methods and analysis

Study setting

Study flow, study settings, and other information are presented in Figure 1 and Table 1. The study recruitment target is 400 participants who start ADT as primary management of *de novo* metastatic prostate cancer or as secondary management for prostate cancer recurrence after localized treatment. Participants can be high-risk M0 or M1 stage, main inclusion criterion is that long-term ADT treatment is started. These men will be randomized 1:1 (200 + 200) to receive either 80 mg of atorvastatin daily or placebo until disease recurrence i.e. development of castration resistance, death, or maximum of ten years. Sample size is based on a power calculation from a previous retrospective study.²³

The study will be carried out in collaboration between urological departments of University Hospitals and central hospitals in Finland, the Herlev University Hospital in Denmark, and the Tartu University Hospital in Estonia (Table 1).

Study data were collected and managed using REDCap electronic data capture tools hosted at Tampere University.^{31,32} Only the primary investigators, study nurses, and registered study co-investigator from each participating site will have access to the platform. All laboratory results, symptoms, and results from imaging studies done at the discretion of the attending clinicians are recorded in the database. All clinical decisions besides the study drug, e.g. use of early chemotherapy, abiraterone, or other drugs in adjunct with ADT will be up to the discretion of the attending clinician and allowed but will also be recorded in the trial database.

Follow-up is continued until development of castration resistance, death, or maximum of 10 years. Participants are given the opportunity to carry on with the intervention even after development of

1
2
3 castration resistance to observe effects on survival. Unblinding will be performed after recruitment
4 target has been reached and all participants have been followed for minimum of 12 months.
5
6
7

8 Castration resistance is defined as either PSA progression (three consecutive rises of PSA measured
9 at least 1 week apart with two > 50% increases over the nadir and PSA > 2 ng/ml) or radiological
10 progression (appearance of two or more lesions in bone scan or soft tissue enlargement as per RECIST
11 criteria) while serum testosterone is at the castrate level (< 50 ng/ml or 1.7 nmol/l).
12
13
14
15

16 For men who initiate statin use during the study period for clinical indications, the study drug is
17 dropped but the study follow-up is continued. These men will be included in the final analysis
18 according to the intention-to-treat principle within their allocated study arm.
19
20
21

22 In case of intolerable side-effects as judged by either the participant or the attending physician, the
23 study drug is stopped, and these men will be analyzed according to the intention-to-treat principle.
24
25
26

27 Participants who discontinue follow-up or deviate from the study protocol for any reason will be
28 given the chance to remain or return to follow-up to allow intention-to-treat analyses.
29
30

31 **Inclusion and exclusion criteria**

32
33
34 Inclusion criteria for participants are histopathologically confirmed metastatic adenocarcinoma of the
35 prostate or high-risk M0 stage recurrent prostate cancer for which androgen deprivation or
36 antiandrogen therapy is initiated no longer than 3 months before recruitment, willingness to
37 participate, and signing of informed consent (Figure 1).
38
39
40

41
42 Exclusion criteria for participants are regular statin use at the time of recruitment or within 6 months
43 of it, previous adverse effects during statin therapy, familial hypercholesterolemia or very high total
44 cholesterol (9.3 mmol/l or above), clinically significant renal (serum creatinine above 170 μ mol/l) or
45 liver insufficiency (serum alanine aminotransferase more than two times above the upper limit of
46 normal range), and use of drugs that may interact with statins (St John's Wort, HIV protease
47 inhibitors, ciclosporin, macrolide antibiotics, fucidic acid, phenytoin, carbamazepine, dronedarone,
48 or oral antifungal medication) (Figure 1).
49
50
51
52
53
54

55 **Study endpoints**

56
57 Primary endpoint is the time to disease progression after starting ADT/antiandrogen therapy.
58 Secondary endpoints are 1); prostate cancer-specific mortality and overall survival, 2); change in
59
60

1
2
3 serum cholesterol during the intervention and its role in predicting time to disease recurrence in the
4 placebo arm, 3); occurrence of adverse tumor traits predicting development of castration resistance
5 in circulating cell free DNA, 4); changes in fasting blood glucose during ADT, 5); occurrence of
6 cardiovascular events during ADT, and 6); Quality of life (QoL) during ADT.
7
8
9

10 **Study flow**

11
12
13 Study flow and schedule is presented in Figure 1 and Table 2. Patients are recruited at urology
14 outpatient clinic at urologists' visits. If the inclusion criteria are met and the exclusion criteria are not
15 and the participant signs informed consent form, he is given a study number (ranging between E-001
16 to E-400) and he receives either 80 mg atorvastatin or placebo according to the study arm randomly
17 allocated for the study number. No blocking or other restrictions will be implemented for
18 randomization. Only the national study coordinator in each country will be able to see which study
19 arm the participant has been randomized to. The participant will then receive first dose of the
20 respective study drug randomized to his study number. The drug boxes and capsules containing
21 atorvastatin and placebo will be of identical outlook. All researchers, nurses, and study participants
22 will remain blinded to the allocation sequence until termination of the study and closure of the study
23 data.
24
25
26
27
28
29
30
31
32

33 Control visits are scheduled at 6-month intervals to suit common clinical practice. Control visits are
34 done by a clinician, complemented with measurements done by a research nurse. For each control
35 visit the participant returns remaining capsules from the previously delivered ration and will receive
36 a new one according to his study number. Number of the remaining capsules will be counted and
37 saved in the trial database to monitor compliance. In every visit serum PSA, alkaline phosphatase,
38 creatinine, and fasting glucose will be measured (Table 2) and the participant is asked about
39 symptoms that are suggestive of metastases and about possible adverse effects of the study drug.
40 Serum creatine kinase is measured at the baseline.
41
42
43
44
45
46
47

48 Blood samples are taken and stored at 6-month intervals to monitor changes in tumor markers and
49 occurrence of adverse tumor characteristics after initiation of ADT. Quality of life during the
50 intervention will be charted once a year using validated WHOQOL-BREF quality of life
51 questionnaire.³³
52
53
54

55 Follow-up is continued until development of castration resistance, drop out from the study, death, or
56 maximum of ten years. Participants developing castration resistance are given an opportunity to carry
57 on with their assigned treatment as statins have been linked to longer cancer-specific survival.
58
59
60

1
2
3 Unblinding will be performed after recruitment target has been reached and all participants have been
4 followed for minimum of 12 months.
5
6

7 Prostate cancer treatment apart from the study drug will be up to the discretion of the attending
8 clinician. All laboratory results, symptoms, and possible imaging results will be recorded in the trial
9 database. All clinical decisions regarding early chemotherapy and imaging will be made on the
10 discretion of the clinician and recorded in the trial database.
11
12
13

14 15 **Stored blood samples** 16

17
18 Separate whole blood (for RNA and DNA isolation), plasma, and serum samples are taken at each
19 control visit at 6-month intervals and stored for mass-spectrometric and nuclear magnetic resonance
20 (NMR)-based determination of serum lipidome. These samples will also be used for RNA and whole
21 genome sequencing of mutations and genetic modifications predicting disease recurrence and
22 metastasis, such as BRCA1/2, ERG, MYC, TP53, ATM, PTEN, and AR splice variants.^{34,35} Also
23 hypoxia markers will be measured.³⁶
24
25
26
27
28

29 For participants with confirmed metastases in the bone or soft tissues, amount of cell free DNA from
30 the plasma will be measured before ADT initiation and again at castration resistance development for
31 sequencing and detection of genetic modifications predicting metastases.^{34,35} Selected patients are
32 also imaged with positron emission tomography (PET) scan using 18F-2-
33 nitroimidazolpentafluoropropylacetamide (EF5)³⁷ to monitor hypoxia and FDG-PET to evaluate
34 immune responses³⁸ in the primary tumor and the metastases during the atorvastatin intervention.
35
36
37
38
39
40

41 **Power calculations** 42

43
44 In a cohort study by Harshman et al.²³, among men starting ADT, 58% of the statin users and 75% of
45 non-users of statins progress to castration resistance during median 5.8 years. We used these crude
46 percentages for sample size calculations.
47
48

49 With alfa and beta values of 0.05 and 0.20 (power=0.80) the difference of 58% vs. 75% would require
50 132 + 132 observations, if group sizes are assumed to be similar. The program “PS - Power and
51 sample size, version 3.1.2” was used for the calculation. To take possible dropouts into account we
52 set the sample size to 400 men, 200 in each study arm.
53
54
55
56

57 The median time to disease progression is assumed to be 12-15 months for patients with *de novo*
58 metastatic disease and 33 months for patients recurring after primary therapy.³⁻⁷ Therefore, the
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

intervention will continue until castration resistance, death, or for maximum of 10 years. Post hoc follow-up will continue after the intervention.

It has to be noted that the number of studies published on this topic is low and, in the absence of randomized evidence on this topic, the power calculation is based on results of epidemiological study prone to residual bias. Therefore, an interim analysis will be performed after the first 100 participants have met the primary endpoint, i.e. progressed into castration resistance. Without lifting the blinding, the power calculations are repeated to verify whether the chosen sample size has adequate statistical power to detect statistically significant difference of the effect size observed between the randomization groups at that time. If the calculations suggest that a larger sample size is needed for the trial, the study protocol will be amended with updated recruitment target.

Statistical methods

Distribution balance of prostate cancer clinical characteristics such as TNM stage at diagnosis, Gleason score, and PSA at time of diagnosis will be compared between the study arms using chi-square test for categorical variables and Mann-Whitney U-test, Student's t-test, or ANOVA for continuous variables depending on whether they follow normal distribution.

Recurrence-free time, i.e. time from ADT initiation to castration resistance, will be compared between the study arms using Kaplan-Meier curves and log-rank test. Risk of death, as well as risk for occurrence of adverse tumor traits among men receiving atorvastatin compared to men receiving placebo will be estimated using Cox proportional hazards regression.

Statistical significance of the association between changes in serum lipid levels and occurrence of adverse tumor genomic traits will be estimated using ANOVA or Mann-Whitney U-test depending on the distribution normality.

Subgroup analyses will be performed stratified by type of ADT or antiandrogen therapy initially selected; GnRH agonists/antagonists, antiandrogen, orchiectomy, or other. Men who start with antiandrogen therapy often change to GnRH agonists/antagonists or orchiectomy when PSA increases during ADT. This is allowed and PSA recurrence during antiandrogen therapy is not considered as disease progression as serum testosterone needs to be at castrate level as well for meeting the primary endpoint.

Another subgroup analysis will be stratified by whether or not the participants have received local therapy (radiation or surgery) for prostate cancer in addition to ADT and by type of additional therapy

1
2
3 participant has received; docetaxel, abiraterone, enzalutamide, or apalutamide at hormone-sensitive
4 stage in addition to ADT.
5

6
7 All analyses will include only participants with available data, imputations will not be used.
8
9

10 **Ethics and dissemination**

11
12
13 This study is approved by the regional ethics committee of Pirkanmaa Hospital District, Science
14 center, Tampere, Finland (R18065M). All participants read and sign informed consent form before
15 study entry. The results of this study will be published in international peer reviewed journals.
16
17

18
19 The trial is ethical for the following reasons 1); The study aims to improve treatment of metastatic
20 prostate cancer, which is the second most common cause of cancer death in Western countries, 2);
21 the potential scientific and societal benefits from the project are substantial. If the study hypothesis
22 proves to be right, it will provide an entirely new way to prevent and/or delay progression of
23 metastatic prostate cancer with atorvastatin, a drug that is cheap, well-tolerated, and with established
24 cardiovascular benefits, 3); the study drug (atorvastatin) is known to be well-tolerated and it is
25 currently widely used in management of hypercholesterolemia and cardiovascular disease. The
26 adverse effects caused by the drug are usually mild and transient after stopping the study drug, and
27 4); randomized, placebo-controlled design ensures the study will produce highest quality evidence
28 that will change prostate cancer treatment guidelines if the hypothesis proves to be right.
29
30
31
32
33
34
35

36
37 After publication of results for the primary endpoints, anonymized summary metadata and statistical
38 code will be made openly available. The data will not include any information that could make it
39 possible to identify a given participant.
40
41
42

43 **Quality control**

44
45
46 The study steering committee includes investigators from each participating recruitment center. The
47 steering committee will meet twice a year to oversee trial progression of the recruitment, integrity of
48 collected data and discuss possible protocol amendments.
49
50

51
52 External trained study monitors independent from the study sponsors ensure the data quality and good
53 clinical practice by making regular yearly check-up visits to participating study centers. This will be
54 separately arranged in each participating country.
55
56
57

58 **Reporting and registering of adverse effects**

1
2
3 The participants are advised to contact the researchers in case of suspected adverse effect related to
4 the study drug. If the side-effects are intolerable the study drug will be discontinued. In uncertain
5 cases serum levels of creatine kinase, alanine aminotransferase and creatinine are checked to see if
6 any of these have changed considerably compared to the baseline. If the laboratory tests are not
7 normal, or if the participant or the attending physician finds the side-effects alarming the study drug
8 will be discontinued. Study database records specifically most common adverse effects muscular
9 pain, elevated fasting blood glucose (> 6,1 mmol/l) and elevated serum creatine kinase (>280 U/l),
10 even when they do not lead to discontinuation of the study drug.
11
12
13
14
15
16
17

18 Trial database includes separate question for serious adverse effects as evaluated by CTCAE criteria,
19 version 5.0. If serious side-effects are reported, trial database asks to fulfill separate query where
20 detailed description of the adverse effect is given according to CTCAE criteria. Study sponsor and
21 coordinator will be automatically notified via e-mail if serious adverse effect is reported in the
22 database. All serious adverse effect that threatens life or health are reported to national authority
23 (FIMEA in Finland) within 7 days of detection. If a life-threatening adverse effect is suspected
24 blinding will be lifted for the participant in case to see whether he has received atorvastatin or placebo.
25 Unexpected adverse effects will be reported to national authority within 15 days of detection.
26
27
28
29
30
31
32

33 **Patients and public involvement**

34
35 In the design phase of the trial, primary investigator presented the study protocol in numerous public
36 events, including patient advocacy group meetings, giving opportunity for the audience to give
37 feedback and suggestions how to improve the study. Patient advocacy organizations of prostate
38 cancer patients are actively involved in finding subjects for the study through announcements in their
39 journals and by allowing investigators frequently promote the study in their meetings. Study results
40 will be reported also in patient organization journals and social media sites for maximum visibility
41 and distribution of trial outcomes.
42
43
44
45
46
47
48

49 **References**

- 50
51 1. Finnish cancer registry statistics: <http://stats.cancerregistry.fi/stats/eng/veng0003m0.html>
52
53 2. Mäklin S, Rissanen P. Cancer expenses in Finland:
54 <http://www.cancer.fi/@Bin/47734/Syöpien+aiheuttamat+kustannukset.pdf>
55
56 3. Ross RW Xie W, Regan MM, Pomerantz M, *et al.* Efficacy of androgen deprivation therapy
57 (ADT) in patients with advanced prostate cancer: association between Gleason score,
58
59
60

- 1
2
3 prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. *Cancer*
4 2008;**112**:1247-53. doi: 10.1002/cncr.23304.
5
6
7 4. Botrel TE, Clark O, Lima Pompeo AC, *et al.* Efficacy and Safety of Combined Androgen
8 Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic
9 Hormone-Naïve Prostate Cancer: A Systematic Review and Meta-Analysis. *PLoS One*
10 2016;**11**:e0157660. doi: 10.1371/journal.pone.0157660.
11
12
13 5. Sweeney CJ, Chen YH, Carducci M, *et al.* Chemohormonal Therapy in Metastatic Hormone-
14 Sensitive Prostate Cancer. *N Engl J Med* 2015;**373**:737-46. doi: 10.1056/NEJMoa1503747
15
16
17 6. Seo WI, Kang PM, Kim TH, *et al.* Primary androgen deprivation therapy for prostate cancer
18 in koreans: a retrospective multicenter study. *World J Mens Health*. 2014;**32**(3):159-66.
19
20
21 7. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM. Intermittent
22 hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. *BJU Int*
23 2012;**110**:1262-9. doi: 10.1111/j.1464-410X.2012.11120.x.
24
25
26 8. Arthur R, Møller H, Garmo H, *et al.* Association between baseline serum glucose,
27 triglycerides and total cholesterol, and prostate cancer risk categories. *Cancer Med*
28 2016;**5**:1307-18. doi: 10.1002/cam4.665
29
30
31 9. Murtola TJ, Syväälä H, Pennanen P, *et al.* Comparative effects of high and low-dose
32 simvastatin on prostate epithelial cells: the role of LDL. *Eur J Pharmacol* 2011;**673**:96-100.
33 doi: 10.1016/j.ejphar.2011.10.022.
34
35
36 10. Murtola TJ, Syväälä H, Pennanen P, *et al.* The importance of LDL and cholesterol metabolism
37 for prostate epithelial cell growth. *PLoS One* 2012;**7**:e39445. doi:
38 10.1371/journal.pone.0039445.
39
40
41 11. Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor
42 microenvironment. *Trends Cell Biol* 2014;**24**:472-8. doi: 10.1016/j.tcb.2014.06.001.
43
44
45 12. Herber DL, Cao W, Nefedova Y *et al.* Lipid accumulation and dendritic cell dysfunction in
46 cancer. *Nat Med* 2010;**16**:880-6. doi: 10.1038/nm.2172
47
48
49 13. Han W, Gao S, Barrett D, *et al.* Reactivation of androgen receptor-regulated lipid biosynthesis
50 drives the progression of castration-resistant prostate cancer. *Oncogene* 2018;**37**:710-21. doi:
51 10.1038/onc.2017.385.
52
53
54 14. Raval AD, Thakker D, Negi H, *et al.* Association between statins and clinical outcomes
55 among men with prostate cancer: a systematic review and meta-analysis. *Prostate Cancer*
56 *Prostatic Dis* 2016;**19**:222. doi: 10.1038/pcan.2016.3
57
58
59
60

15. Barfeld SJ, Itkonen HM, Urbanucci A, *et al.* Androgen-regulated metabolism and biosynthesis in prostate cancer. *Endocr Relat Cancer* 2014;**21**:T57-66. doi: 10.1530/ERC-13-0515.
16. Dambal S, Howard LE, Allott EH, *et al.* Serum Lipids prior to Starting Androgen Deprivation Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the SEARCH Database. *J Urol* 2020;**203**:120-7. doi: 10.1097/JU.0000000000000494
17. Van Rompay MI, Solomon KR, Nickel JC, *et al.* Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications. *Eur J Cancer* 2019;**112**:118-26. doi: 10.1016/j.ejca.2018.11.033.
18. Kumar A, Riviere P, Luterstein E, *et al.* Associations among statins, preventive care, and prostate cancer mortality. *Prostate Cancer Prostatic Dis* 2020. doi: 10.1038/s41391-020-0207-5
19. Murai T. Cholesterol lowering: role in cancer prevention and treatment. *Biol Chem* 2015;**396**:1-11. doi: 10.1515/hsz-2014-0194.
20. Garcia-Ruiz C, Morales A, Fernandez-Checa JC. Statins and protein prenylation in cancer cell biology and therapy. *Anticancer Agents Med Chem* 2012;**12**:303-15. doi: 10.2174/187152012800228715
21. Armandari I, Hamid AR, Verhaegh G, *et al.* Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. *Prostate Int* 2014;**2**:105-13. doi: 10.12954/PI.14063.
22. Mokarram P, Alizadeh J, Razban V, *et al.* Interconnection of Estrogen/Testosterone Metabolism and Mevalonate Pathway in Breast and Prostate Cancers. *Curr Mol Pharmacol* 2017;**10**:86-114. doi: 10.2174/1874467209666160112125631.
23. Harshman LC, Wang X, Nakabayashi M, *et al.* Statin use at the time of initiation of androgen deprivation therapy and time to progression in patients with hormone-sensitive prostate cancer. *JAMA Oncol* 2015;**1**:495-504. doi: 10.1001/jamaoncol.2015.0829.
24. Jung J, Lee C, Lee C, *et al.* Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer. *Korean J Urol* 2015;**56**:630-6. doi: 10.4111/kju.2015.56.9.630.
25. Syväälä H, Pennanen P, Bläuer M, *et al.* Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. *Biochem Biophys Res Commun* 2016;**481**:46-50. doi: 10.1016/j.bbrc.2016.11.021

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
26. Yang H, Pang L, Hu X, *et al.* The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis. *J Clin Pharm Ther* 2020;**45**:488-95. doi: 10.1111/jcpt.13092
27. Lv HL, Jin DM, Liu M, *et al.* Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. *Pharmacol Res* 2014;**81**:64-73. doi: 10.1016/j.phrs.2014.02.006.
28. Murtola T, Riikonen J, Syvälä H, *et al.* Atorvastatin Versus Placebo for Prostate Cancer Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical Trial. *Eur Urol* 2018;**74**:697-701. doi: 10.1016/j.eururo.2018.06.037.
29. Longo J, Hamilton RJ, Masoomian M, *et al.* A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. *Prostate Cancer Prostatic Dis* 2020;**23**:630-37. doi: 10.1038/s41391-020-0221-7
30. Hamilton RJ, Ding K, Crook JM, *et al.* The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. *Eur Urol* 2020 (article in press) <https://doi.org/10.1016/j.eururo.2020.12.031>
31. Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (REDCap) – A metadata-driven methodology and workflow process for providing translational research informatics support. *J Biomed Inform* 2009;**42**:377-81. doi: 10.1016/j.jbi.2008.08.010
32. Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an international community of software partners. *J Biomed Inform* 2019;**95**:103208. doi: 10.1016/j.jbi.2019.103208.
33. WHOQOL-BREF, The World Health Organization Quality of Life, THL
34. Mateo J, Boysen G, Barbieri CE, *et al.* DNA repair in prostate cancer: biology and clinical implications. *Eur Urol* 2017;**71**:417-25. doi: 10.1016/j.eururo.2016.08.037
35. Xu J, Qiu Y. Role of androgen receptor splice variants in prostate cancer metastasis. *Asian J Urol* 2016;**3**:177-84. doi: 10.1016/j.ajur.2016.08.003.
36. Le QT, Courter D. Clinical biomarkers for hypoxia targeting. *Cancer Metastasis Rev* 2008;**27**:351-62. doi: 10.1007/s10555-008-9144-9
37. Stieb S, Eleftheriou A, Warnock G, *et al.* Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. *Eur J Nucl Med Mol Imaging* 2018;**45**:2201-17. doi: 10.1007/s00259-018-4116-y
38. Hunt SJ, Seraj SM, Alavi A. PET Assessment of Immune Effects from Interventional Oncology Procedures. *PET Clin* 2019;**14**:477-85. doi: 10.1016/j.cpet.2019.06.007.

1
2
3 **Authors' contributions:** Teemu Murtola is the primarily investigator of this study and designed the
4 study with the help from other authors. Aino Siltari and Teemu Murtola wrote the first draft of the
5 manuscript. All other authors further contributed to manuscript preparation and accepted the final
6 version of the manuscript.
7
8
9

10
11 **Funding:** This study is supported by grants from Finnish Cancer Foundation (grant numbers 024194
12 and 3122800563 (TJM) and 16112016 (TL)), Nordic Cancer Union (grant number MS793 (TJM)),
13 Päivikki and Sakari Sohlberg Foundation (grant number 31228005901 (AS)), competitive research
14 grant of Pirkanmaa hospital district (grant number 9X032 (TJM) and grant X51001 (TL)), and the
15 Academy of Finland (grants numbers 322098 (TL), and 3121330724 (TJM)).
16
17
18
19

20 **Disclaimer:** None of the funders has a role in the design, management, analysis or interpretation of
21 data, or writing and publication of results.
22
23
24

25 **Competing interests:** Peter Østergren: honorarium as speaker from Ipsen A/S, Ferring
26 Pharmaceuticals, and Astellas Pharma. Mikkel Fode: consultant fees and honorarium as speaker from
27 Astellas and Ferring. Hanna Ronkainen: consultant fees from Bayer AB and honorarium as speaker
28 from Sanofi. Teemu J Murtola: Consultant fees from Astellas, Janssen, speaker's honorarium from
29 Astellas, Janssen and Sanofi, participation in scientific meetings at the expense of Ferring, Pfizer, and
30 Sanofi, stockholder for Arocell AB. Peter Boström: consultant fees from Astellas Pharma. All other
31 authors: No competing interests to declare.
32
33
34
35
36
37

38 **Data sharing:** There are no additional unpublished data at this point of this study.
39
40

41 Captions to Figure and Tables:
42
43
44

45 Figure 1. Study flow with inclusion and exclusion criteria.
46
47

48 Table 1. Study setting of Impact of atorvastatin on prostate cancer after initiation of androgen
49 deprivation therapy -clinical trial
50
51


52 Table 2. Study flow and timing of the laboratory and blood sample collection
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study settings	
Primary registry and trial identifying number	Clinicaltrials.gov NCT04026230
Date of registration in primary registry	July 19, 2019
Secondary identifying numbers	Eudra-CT: 2016-004774-17, Protocol code: ESTO2
Source(s) of monetary or material support	Tampere University Hospital, Finland
Primary sponsor	Tampere University Hospital, Finland
Secondary sponsor(s)	Helsinki University Hospital, Turku University Hospital, Central Finland Central Hospital, Kuopio University Hospital, Oulu University Hospital, Finland, Herlev Hospital, Denmark, University Hospital Tartu, Estonia
Contact for public queries	Tampere University Hospital, Teemu Murtola, MD, PhD
Contact for scientific queries	Tampere University Hospital, Teemu Murtola, MD, PhD
Public title	Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy
Scientific title	Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial FinnProstata XV
Countries of recruitment	Finland, Denmark, Estonia
Health condition studied	Metastatic or recurrent prostate cancer
Intervention	Active comparator: Capsules of atorvastatin 80 mg, Placebo comparator: Similar capsules as in the atorvastatin arm, but without the active ingredient
Key inclusion and exclusion criteria	Inclusion criteria: Histopathologically confirmed metastatic adenocarcinoma of the prostate for which androgen deprivation or antiandrogen therapy is initiated no longer than 3 months before as the primary treatment Willingness to participate and signing of informed consent Exclusion criteria: Statin use at the time of recruitment or within 6 months of it, Previous adverse effects during statin therapy, familial hypercholesterolemia or very high total cholesterol, clinically significant renal or liver insufficiency, use of drugs that may interact with statins
Sexes eligible for study:	Male
Accepts healthy volunteers	No
Study type	Interventional, Allocation: randomized, Intervention model: parallel assignment with 1:1 allocation ratio, Masking: double blind (subject, caregiver, investigator, outcomes assessor), Primary purpose: prevention, Phase III
Date of first enrolment	July 2019
Target sample size	400
Recruitment status	Recruiting
Primary outcome(s)	Castration resistance
Key secondary outcomes	Lipid levels, Prostate cancer mortality and overall survival, Circulating cell free DNA, Fasting blood glucose, Occurrence of cardiovascular events during ADT, Quality of life

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Study flow and timing of the laboratory and blood sample collection								
TIMEPOINT	Enrollment	Allocation	Follow-up					
			0	6m	12m	18m	24m	etc*
ENROLLMENT:								
Eligibility screen	x							
Informed consent	x							
Allocation		x						
INTERVENTIONS:+								
Atorvastatin			x	x	x	x		
Placebo			x	x	x	x		
ASSESSMENTS:								
Serum PSA			x	x	x	x		
Alkaline phosphatase			x	x	x	x		
Creatinine	x		x	x	x	x		
Serum creatine kinase	x							
Alanine aminotransferase	x							
Fasting blood glucose	x		x	x	x	x		
Lipid levels	x		x	x	x	x		
Cell free DNA (subgroup)^	x							
QoL	x			x			x	
m=month, y=year, QoL=quality of life, PSA=prostate-specific antigen								
*follow-up until disease recurrence, death, or max. 10 years								
+ allocation 1:1 to have either 80 mg atorvastatin or placebo daily								
^Cell free DNA is measured before allocation and after occurrence of castration resistance.								



Study flow with inclusion and exclusion criteria.

284x208mm (72 x 72 DPI)



STANDARD PROTOCOL ITEMS: RECOMMENDATIONS FOR INTERVENTIONAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____ 1 _____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____ 2 _____
	2b	All items from the World Health Organization Trial Registration Data Set	_____
Protocol version	3	Date and version identifier	_____ 2 _____
Funding	4	Sources and types of financial, material, and other support	_____ 14 _____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____ 1 _____
	5b	Name and contact information for the trial sponsor	_____ 1 _____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____ 14 _____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____ 10 _____

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention ___ 3-4 ___

4

5

6 6b Explanation for choice of comparators ___ 3-4 ___

7

8 Objectives 7 Specific objectives or hypotheses ___ 5 ___

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) ___ 5-6 ___

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained ___ 5-6 ___

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) ___ 6 ___

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered ___ 7-8 ___

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) ___ 6 ___

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) ___ 7-8 ___

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial ___ 8 ___

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended ___ 6-7 ___

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) ___ 7-8, Table 2 ___

41

42

43

44

45

46

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including _____ 8-9 _____
 2 clinical and statistical assumptions supporting any sample size calculations

3
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size _____ 8-9 _____
 5

6 **Methods: Assignment of interventions (for controlled trials)**

7
 8 Allocation:

9
 10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any _____ 7 _____
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
 13 or assign interventions
 14
 15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, _____ 7 _____
 17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
 18 mechanism
 19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to _____ 7 _____
 21 interventions
 22
 23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome _____ 7 _____
 25 assessors, data analysts), and how
 26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's _____ 7 _____
 28 allocated intervention during the trial
 29
 30

31 **Methods: Data collection, management, and analysis**

32
 33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related _____ 7-8 _____
 34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
 35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
 36 Reference to where data collection forms can be found, if not in the protocol
 37

38
 39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be _____ 6 _____
 40 collected for participants who discontinue or deviate from intervention protocols
 41
 42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____5_____
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	___9-10_____
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	___9-10_____
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	___10_____
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	___10_____
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	___6, 11_____
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	___11_____
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	___10_____
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	___10_____
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	___10_____
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____7_____
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____5_____
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____15_____
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____5_____
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____10_____
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](https://creativecommons.org/licenses/by-nc-nd/3.0/)" license.
 40
 41
 42

BMJ Open

Randomized double-blind phase 3 clinical study testing impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy - study protocol

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-050264.R1
Article Type:	Protocol
Date Submitted by the Author:	16-Dec-2021
Complete List of Authors:	Siltari, Aino; Tampere University, Faculty of Medicine and Health Technology; University of Helsinki, Faculty of Medicine, Pharmacology Riikonen, Jarno; Tampere University Hospital, Department of Urology Koskimäki, Juha; Tampere University Hospital, Department of Urology Pakarainen, Tomi; Tampere University Hospital, Department of Urology Ettala, Otto; University of Turku Boström, Peter; University of Turku Seikkula, Heikki; Central Finland Central Hospital Kotsar, Andres; Tartu University Hospital Tammela, Teuvo; University of Tampere Helminen, Mika; Tampere University, Health Sciences Raittinen, Paavo; Aalto University School of Science and Technology, Department of Mathematics and Systems Analysis Lehtimäki, Terho; Tampere University, Department of Clinical Chemistry Fode, Mikkel; Herlev Hospital Østergren, Peter; Herlev and Gentofte University Hospital, Department of Urology Borre, Michael; Aarhus Universitetshospital, Department of Urology Rannikko, Antti; Helsinki University and Helsinki University Hospital, Department of Urology Marttila, Timo; Seinäjoki Central Hospital, Department of Urology Salonen, Arto; Kuopio University Hospital Ronkainen, Hanna; Oulu University Hospital Löffeler, Sven; Vestfold Hospital Trust, Section of Urology Murtola, Teemu J ; Tampere University Hospital, Department of Urology
Primary Subject Heading:	Urology
Secondary Subject Heading:	Oncology
Keywords:	Prostate disease < UROLOGY, Clinical trials < THERAPEUTICS, Urological tumours < ONCOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



1 2 3 **1 Randomized double-blind phase 3 clinical study testing impact of** 4 **2 atorvastatin on prostate cancer progression after initiation of androgen** 5 **3 deprivation therapy - study protocol** 6 7 8 9

10
11 4 Aino Siltari¹, Jarno Riikonen², Juha Koskimäki², Tomi Pakarainen², Otto Ettala³, Peter Boström³,
12 5 Heikki Seikkula⁴, Andres Kotsar⁵, Teuvo LJ Tammela^{1,2}, Mika Helminen^{7,8}, Paavo V Raittinen⁹,
13 6 Terho Lehtimäki^{1,10}, Mikkel Fode¹¹, Peter Østergren¹¹, Michael Borre¹², Antti Rannikko¹³, Timo
14 7 Marttila¹⁴, Arto Salonen¹⁵, Hanna Ronkainen¹⁶, Sven Löffeler¹⁷, Teemu J Murtola^{1,2*}
15
16
17
18

19 8 ¹Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland, ²TAYS Cancer
20 9 Center, Department of Urology, Tampere, Finland, ³Turku University Hospital and University of
21 10 Turku, Turku, Finland, ⁴Central Finland Central Hospital, Jyväskylä, Finland, ⁵Tartu University
22 11 Hospital, Department of Urology, Tartu, Estonia, ⁶Fimlab laboratories, Department of Pathology,
23 12 Tampere, Finland, ⁷Tampere University Hospital, Research Services, Tampere, Finland, ⁸Tampere
24 13 University, Faculty of Social Sciences, Health Sciences, Tampere Finland, ⁹Aalto University School
25 14 of Science, Department of Mathematics and Systems Analysis, Espoo, Finland, ¹⁰Fimlab
26 15 Laboratories, Department of Clinical Chemistry, Tampere, Finland, ¹¹Department of Urology, Herlev
27 16 and Gentofte Hospital, Denmark, ¹²Aarhus University Hospital, Department of Urology, Aarhus,
28 17 Denmark, ¹³Helsinki University and Helsinki University Hospital, Department of Urology, Helsinki,
29 18 Finland ¹⁴Seinäjoki Central Hospital, Department of Urology, Seinäjoki, Finland, ¹⁵Kuopio
30 19 University Hospital, Department of Urology, Kuopio, Finland, ¹⁶Oulu University Hospital,
31 20 Department of Urology, Oulu, Finland, ¹⁷ Vestfold Hospital Trust, Section of Urology, Tønsberg,
32 21 Norway
33
34
35
36
37
38
39
40
41
42
43

44 22 *corresponding author: Teemu J Murtola, Department of Urology, Tampere University Hospital, PL
45 23 2000, 33521 Tampere, Finland, teemu.murtola@tuni.fi, telephone: +358 (0) 294 52 11.
46
47
48
49
50
51
52

53 27 Keywords: Prostate cancer; castration-resistant prostate cancer; androgen deprivation therapy;
54 28 atorvastatin; randomized clinical trial
55
56
57

58 30 Word count: 4069 (excluding title page, references, figures, and tables)
59
60 31

1 Abstract

2 Introduction

3 Blood cholesterol is likely a risk factor for prostate cancer prognosis and use of statins is associated
4 with lowered risk of prostate cancer recurrence and progression. Furthermore, use of statins has been
5 associated with prolonged time before development of castration resistance (CR) during androgen
6 deprivation therapy (ADT) for prostate cancer. However, the efficacy of statins on delaying
7 castration-resistance has not been tested in a randomized placebo-controlled setting.

8 This study aims to test statins' efficacy compared to placebo in delaying development of CR during
9 ADT treatment for primary metastatic or recurrent prostate cancer. Secondary aim is to explore effect
10 of statin intervention on prostate cancer mortality and lipid metabolism during ADT.

11 Methods and analysis

12
13 In this randomized placebo-controlled trial, a total of 400 men with *de novo* metastatic prostate cancer
14 or recurrent disease after primary treatment and starting ADT will be recruited and randomized 1:1
15 to use daily 80 mg of atorvastatin or placebo. All researchers, study nurses, and patients will be
16 blinded throughout the trial. Patients are followed until disease recurrence or death. Primary outcome
17 is time to formation of CR after initiation of ADT. Serum lipid levels (total cholesterol, HDL, LDL,
18 and triglycerides) are analyzed to test whether changes in serum cholesterol parameters during ADT
19 predict length of treatment response. Furthermore, the trial will compare quality of life,
20 cardiovascular morbidity, changes in blood glucose and circulating cell-free DNA, and urine lipids
21 during trial.

22 Ethics and dissemination

23 This study is approved by the Regional ethics committees of the Pirkanmaa Hospital District, Science
24 center, Tampere, Finland (R18065M) and Tarto University Hospital, Tarto, Estonia (319/T-6). All
25 participants read and sign informed consent form before study entry. Clinicaltrial.gov:
26 NCT04026230, Eudra-CT: 2016-004774-17, protocol code: ESTO2, protocol date September 10th
27 2020 and version 6. After publication of results for the primary endpoints, anonymized summary
28 metadata and statistical code will be made openly available. The data will not include any information
29 that could make it possible to identify a given participant.

1
2
3 1 Keywords: Prostate cancer; castration-resistant prostate cancer; androgen deprivation therapy;
4 atorvastatin; randomized clinical trial
5 2
6 3
7
8

9 4 Strengths and limitations of this study
10
11

- 12 5 • First randomized placebo-controlled phase 3 clinical study on effects of atorvastatin on
13 prostate cancer progression during ADT treatment
- 14 6 • Multicenter study in Finland, Denmark, Estonia, and Norway
- 15 7 • As a limiting factor, only minority of prostate cancer cases are advanced and large proportion
16 8 of potential participants are ineligible due to using statins already. Thus, study enrolment will
17 9 take several years
18 10
19 11
20 12
21 13
22 14
23 15
24 16
25 17

26 13 Introduction

27
28
29 14 Prostate cancer (PCa) is the most common cancer in Finnish men and a major public health burden
30 15 causing annually around 900 cancer deaths in Finland and the yearly costs caused by the disease are
31 16 estimated to reach 180 million euros.¹⁻² However, not all prostatic malignancies are lethal; only 10-
32 17 20% of tumors advance to metastases and eventually into a fatal stage. Advanced PCa is treated by
33 18 androgen deprivation therapy (ADT). Eventually, however, PCa progress despite the ADT treatment
34 19 and forms state called castration resistance. Thus, castration resistance is clinically defined as a
35 20 moment when prostate cancer no longer responds to ADT treatment. Median time to castration
36 21 resistance is 12-15 months and 45 months to death in patients who have started ADT for metastatic
37 22 prostate cancer.³⁻⁷ In men who start ADT for disease recurrence after primary treatment, median
38 23 failure-free survival time is 33 months and 70 months to death.³
39
40
41
42
43
44
45
46
47
48

49 25 Blood cholesterol is likely a risk factor for prostate cancer prognosis; risk of disease recurrence after
50 26 primary treatment is significantly elevated in men with hypercholesterolemia.⁸ Laboratory studies
51 27 have demonstrated the importance of cholesterol for prostate cancer cell growth.^{9,10} Furthermore,
52 28 upregulation of intracellular lipid production and ensuing lipid accumulation is essential in surviving
53 29 hypoxic tumor microenvironment.¹¹ In prostate cancer cells it also assists in evading host-tumor
54 30 immune response.¹² Also, upregulation of intracellular cholesterol production appears to be central
55 31 for development of castration resistance.¹³
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Lipid metabolism is emerging as a new risk factor for prostate cancer progression. The role of
2 cholesterol is important in development of castration resistance, and inhibition of intracellular lipid
3 production interferes with androgen receptor (AR) signaling essential for prostate cancer
4 progression¹³⁻¹⁵. Cholesterol is precursor for intracellular androgen production, a central mechanism
5 for prostate cancer cells to overcome ADT.^{13,15} A recent study suggests that some of the serum basic
6 lipid parameters may have increased association with development of castration resistance and
7 metastasis especially in statin-naïve patients.¹⁶ Clarification of the role of lipid metabolism during
8 ADT will likely provide new tools for control of disease progression and prostate cancer treatment.

9 Use of cholesterol-lowering statin drugs is associated with lowered risk of prostate cancer recurrence
10 and progression; risk of prostate cancer death is reduced by 30% compared to the non-users.^{14,17,18}
11 The anticancer effect may be specifically against progression of the disease and the mechanisms
12 driving it.¹⁹ Statins inhibit the cholesterol-synthesizing mevalonate pathway, which is active in
13 prostate cancer cells.^{10,20} Besides cholesterol, this pathway also produces isoprenoid proteins which
14 are critical for regulation of cell growth and other central cellular control processes.²⁰ Furthermore,
15 steroid hormones such as testosterone are metabolized from cholesterol, thus statins appear to target
16 androgen metabolism, another crucial pathway for prostate cancer growth.^{21,22}

17 Statin use has been reported to prolong efficacy of ADT in prostate cancer as it has been reported to
18 prolong the efficacy of ADT for 8-10 months.^{23,24} Furthermore, statins have been linked to a
19 prolonged response to androgen-signaling targeted drugs abiraterone and enzalutamide used in
20 management of castration-resistant disease.^{25,26}

21 Statins have not been found to affect prostate cancer mortality in trials testing their efficacy in
22 secondary prevention of cardiovascular disease.²⁷ However, in these trials cancer was often an
23 exclusion criterion. On the other hand, it may be that statin treatment has more impact on hormone-
24 dependent cancers which are underrepresented in these studies. In a randomized clinical trial focusing
25 on prostate cancer patients 80 mg of atorvastatin has been found to reduce tumor proliferation activity
26 compared to placebo after minimum exposure of 21 days.²⁸ Similar results were seen after treatment
27 with fluvastatin, although in a non-randomized and uncontrolled setting.²⁹ Nevertheless, clinical
28 efficacy of statins in preventing progression of prostate cancer has not been tested in a randomized
29 placebo-controlled setting. Also, a recent post-hoc study of randomized clinical trial concluded that
30 statin use was associated with decreased overall and PCa-specific mortality in men with ADT.³⁰
31 Therefore, it is important to do a trial testing effects of statins specifically in prostate cancer patients.

1 **Study objective**

2 Primary objective for this phase III randomized double-blind placebo-controlled trial is to explore
3 whether intervention with atorvastatin delays prostate cancer progression i.e. development of
4 castration resistance compared to placebo during androgen deprivation therapy (ADT) for metastatic
5 or recurrent prostate cancer. Secondary objectives include exploring whether atorvastatin lowers
6 prostate cancer-specific or overall mortality compared to placebo, and to demonstrate whether
7 changes in serum lipid parameters predict disease recurrence and occurrence of adverse tumor
8 genomic traits predicting castration resistance among prostate cancer patients during ADT.

9 **Methods and analysis**

10 **Study setting**

11 Study flow, study settings, and other information are presented in Figure 1 and Table 1. The study
12 recruitment target is 400 participants who start ADT as primary management of *de novo* metastatic
13 prostate cancer or as secondary management for prostate cancer recurrence after localized treatment.
14 Participants can be high-risk M0 or M1 stage, main inclusion criterion is that long-term ADT
15 treatment is started. These men will be randomized 1:1 (200 + 200) to receive either 80 mg of
16 atorvastatin daily or placebo until disease recurrence i.e. development of castration resistance, death,
17 or maximum of ten years. Sample size is based on a power calculation from a previous retrospective
18 study.²³

19 The study will be carried out in collaboration between urological departments of University Hospitals
20 and central hospitals in Finland, the Herlev University Hospital in Denmark, the Tartu University
21 Hospital in Estonia, and Vestfold Hospital Trust in Norway (Table 1).

22 Study data are collected and managed using REDCap electronic data capture tools hosted at Tampere
23 University.^{31,32} Only the primary investigators, study nurses, and registered study co-investigator
24 from each participating site will have access to the platform. All laboratory results, symptoms, and
25 results from imaging studies done at the discretion of the attending clinicians are recorded in the
26 database. All clinical decisions besides the study drug, e.g. use of early chemotherapy, abiraterone,
27 or other drugs in adjunct with ADT will be up to the discretion of the attending clinician and allowed
28 but will also be recorded in the REDCap database.

29 Follow-up is continued until development of castration resistance, death, or maximum of 10 years.
30 Participants are given the opportunity to carry on with the intervention even after development of

1
2
3 1 castration resistance to observe effects on survival. Unblinding will be performed after recruitment
4 target has been reached and all participants have been followed for minimum of 12 months.
5 2
6 3

8 4 Castration resistance is defined as either PSA progression (three consecutive rises of PSA measured
9 at least 1 week apart with two > 50% increases over the nadir and PSA > 2 ng/ml) or radiological
10 5 progression (appearance of two or more lesions in bone scan or soft tissue enlargement as per RECIST
11 6 criteria) while serum testosterone is at the castrate level (< 50 ng/ml or 1.7 nmol/l).
12 7
13
14
15

16 8 For men who initiate statin use during the study period for clinical indications, the study drug is
17 9 dropped but the study follow-up is continued. These men will be included in the final analysis
18 10 according to the intention-to-treat principle within their allocated study arm.
19
20
21

22 11 In case of intolerable side-effects as judged by either the participant or the attending physician, the
23 12 study drug is stopped, and these men will be analyzed according to the intention-to-treat principle.
24
25
26

27 13 Participants who discontinue follow-up or deviate from the study protocol for any reason will be
28 14 given the chance to remain or return to follow-up to allow intention-to-treat analyses.
29
30

31 15 **Inclusion and exclusion criteria**

32
33
34 16 Inclusion criteria for participants are histopathologically confirmed metastatic adenocarcinoma of the
35 17 prostate or high-risk M0 stage recurrent prostate cancer for which androgen deprivation or
36 18 antiandrogen therapy is initiated no longer than 3 months before recruitment, willingness to
37 19 participate, and signing of informed consent (Figure 1).
38
39
40
41

42 20 Exclusion criteria for participants are regular statin use at the time of recruitment or within 6 months
43 21 of it, previous adverse effects during statin therapy, familial hypercholesterolemia or very high total
44 22 cholesterol (9.3 mmol/l or above), clinically significant renal (serum creatinine above 170 μ mol/l) or
45 23 liver insufficiency (serum alanine aminotransferase more than two times above the upper limit of
46 24 normal range), and use of drugs that may interact with statins (St John's Wort, HIV protease
47 25 inhibitors, ciclosporin, macrolide antibiotics, fucidic acid, phenytoin, carbamazepine, dronedarone,
48 26 or oral antifungal medication) (Figure 1).
49
50
51
52
53
54

55 27 **Study endpoints**

56
57
58 28 Primary endpoint is the time to disease progression after starting ADT/antiandrogen therapy.
59 29 Secondary endpoints are 1); prostate cancer-specific mortality and overall survival, 2); change in
60

1
2
3 1 serum cholesterol during the intervention and its role in predicting time to disease recurrence in the
4 placebo arm, 3); occurrence of adverse tumor traits predicting development of castration resistance
5 2 in circulating cell free DNA, 4); changes in fasting blood glucose during ADT, 5); occurrence of
6 3 cardiovascular events during ADT, and 6); Quality of life (QoL) during ADT.
7
8
9

10 5 **Study flow**

11
12
13
14 6 Study flow and schedule is presented in Figure 1 and Table 2. Patients are recruited at urology
15 7 outpatient clinic at urologists' visits. If the inclusion criteria are met and the exclusion criteria are not
16 8 and the participant signs informed consent form, he is given a study number (ranging between E-001
17 9 to E-400) and he receives either 80 mg atorvastatin or placebo according to the study arm randomly
18 10 allocated for the study number. No blocking or other restrictions will be implemented for
19 11 randomization. Only the national study coordinator in each country will be able to see which study
20 12 arm the participant has been randomized to. The participant will then receive first dose of the
21 13 respective study drug randomized to his study number. The drug boxes and capsules containing
22 14 atorvastatin and placebo will be identical in appearance. All researchers, nurses, and study
23 15 participants will remain blinded to the allocation sequence until termination of the study and closure
24 16 of the study data.
25
26
27
28
29
30
31
32

33
34 17 Control visits are scheduled at 6-month intervals to suit common clinical practice. Control visits are
35 18 done by a clinician, complemented with measurements done by a research nurse. For each control
36 19 visit the participant returns remaining capsules from the previously delivered ration and will receive
37 20 a new one according to his study number. Number of the remaining capsules will be counted and
38 21 saved in the REDCap, trial database, to monitor compliance. In every visit serum PSA (ng/ml), lipid
39 22 levels (total cholesterol, HDL, LDL, and triglycerides, mmol/l), alkaline phosphatase (U/l), creatinine
40 23 ($\mu\text{mol/l}$), and fasting glucose (mmol/l) will be measured (Table 2) and the participant is asked about
41 24 symptoms that are suggestive of metastases and about possible adverse effects of the study drug.
42 25 Serum creatine kinase (U/l) and alanine aminotransferase (U/l) is also measured at each visit.
43
44
45
46
47
48
49

50 26 Blood samples are taken and stored at 6-month intervals to monitor changes in tumor markers and
51 27 occurrence of adverse tumor characteristics after initiation of ADT. Quality of life during the
52 28 intervention will be charted once a year using validated WHOQOL-BREF quality of life
53 29 questionnaire.³³
54
55
56
57

58 30 Follow-up is continued until development of castration resistance, drop out from the study, death, or
59 31 maximum of ten years. Participants developing castration resistance are given an opportunity to carry

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 on with their assigned treatment as statins have been linked to longer cancer-specific survival.
2 Unblinding will be performed after recruitment target has been reached and all participants have been
3 followed for minimum of 12 months.

4 Prostate cancer treatment apart from the study drug will be up to the discretion of the attending
5 clinician. All laboratory results, symptoms, and possible imaging results will be recorded in the
6 REDCap database. All clinical decisions regarding early chemotherapy and imaging will be made on
7 the discretion of the clinician and recorded in the REDCap database.

8 **Stored blood samples**

9 Separate whole blood (for RNA and DNA isolation), plasma, and serum samples are taken at each
10 control visit at 6-month intervals and stored for mass-spectrometric and nuclear magnetic resonance
11 (NMR)-based determination of serum lipidome. These samples will also be used for RNA and whole
12 genome sequencing of mutations and genetic modifications predicting disease recurrence and
13 metastasis, such as BRCA1/2, ERG, MYC, TP53, ATM, PTEN, and AR splice variants.^{34,35} Also
14 hypoxia markers will be measured.³⁶

15 For participants with confirmed metastases in the bone or soft tissues, amount of cell free DNA from
16 the plasma will be measured before ADT initiation and again at castration resistance development for
17 sequencing and detection of genetic modifications predicting metastases.^{34,35} Selected patients are
18 also imaged with positron emission tomography (PET) scan using 18F-2-
19 nitroimidazolpentafluoropropylacetamide (EF5)³⁷ to monitor hypoxia and FDG-PET to evaluate
20 immune responses³⁸ in the primary tumor and the metastases during the atorvastatin intervention.

21 **Sample size calculation**

22 In a cohort study by Harshman et al.²³, among men starting ADT, 58% of the statin users and 75% of
23 non-users of statins progress to castration resistance during median 5.8 years. We used these crude
24 percentages for sample size calculations.

25 With alpha and beta values of 0.05 and 0.20 (power=0.80), sample size of 400 men will be enough
26 to detect a risk difference with HR 0.65 (Figure 2). We assume 10% drop-out rate in each study arm.
27 The program “PS - Power and sample size, version 3.1.2” was used for the calculation.

28 The median time to disease progression is assumed to be 12-15 months for patients with *de novo*
29 metastatic disease and 33 months for patients recurring after primary therapy.³⁻⁷ Therefore, the

1
2
3 1 intervention will continue until castration resistance, death, or for maximum of 10 years. Post hoc
4
5 2 follow-up will continue after the intervention. A 3 months' difference in time to castration resistance
6
7 3 between the study arms will be considered clinically significant.
8

9 4 It has to be noted that the number of studies published on this topic is low and, in the absence of
10
11 5 randomized evidence on this topic, the power calculation is based on results of epidemiological study
12
13 6 prone to residual bias. Therefore, an interim analysis will be performed after the first 100 participants
14
15 7 have met the primary endpoint, i.e. progressed into castration resistance. Without lifting the blinding,
16
17 8 the power calculations are repeated to verify whether the chosen sample size has adequate statistical
18
19 9 power to detect statistically significant difference of the effect size observed between the
20
21 10 randomization groups at that time. If the calculations suggest that a larger sample size is needed for
22
23 11 the trial, the study protocol will be amended with updated recruitment target.

24 12 **Statistical methods**

25
26
27 13 Distribution balance of prostate cancer clinical characteristics such as TNM stage at diagnosis,
28
29 14 Gleason score, and PSA at time of diagnosis will be presented in a patient characteristics table,
30
31 15 stratified by study arms. Categorical variables are displayed as absolute count frequencies and relative
32
33 16 frequencies, i.e., proportion within study arm. Continuous variables are presented as median and
34
35 17 interquartile range. Minimum and maximum values are not shown to ensure anonymity of the
36
37 18 participants.

38 19 Recurrence-free survival, i.e. time from ADT initiation to castration resistance, will be analyzed by
39
40 20 using Kaplan-Meier (KM) estimator, stratified by study arm. The statistical significance of the
41
42 21 difference between the survival estimates is tested with log-rank test. No adjustments will be used for
43
44 22 KM estimator as the study intervention is randomized. Risk of death, as well as risk for occurrence
45
46 23 of adverse tumor traits among men receiving atorvastatin compared to men receiving placebo will be
47
48 24 estimated using Cox proportional hazards regression.

49 25 Univariate analysis of changes in serum lipid levels is performed by calculating the difference after
50
51 26 – before for each participant. The statistical significance of the difference between the study arms is
52
53 27 analyzed by Mann-Whitney U-test (or by t-test if under normality). These results are complemented
54
55 28 with boxplots. Multivariable analysis for difference in serum lipid levels between the study arms are
56
57 29 performed by fitting a logistic regression model such that the study arm is used as the response
58
59 30 variable whereas lipid level differences are used as predictors (i.e., each lipid level difference as an
60
31 independent predictor). Lipid levels are expected to display heavy multi-collinearity; therefore,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 variance inflation factors (VIF) are calculated for each coefficient afterwards, and possible
2 adjustments made by dropping predictors with extreme VIFs (> 10).

3 The occurrence of adverse tumor genomic traits will be analysed by calculating the proportion of
4 participants developing adverse tumor genomic traits. The statistical significance between the
5 proportions is tested by proportions test.

6 The WHOQOL-BREF patient reported outcome (PRO) of the quality-of-life is analysed by tabulating
7 absolute and relative frequencies. Chi-squared test for homogeneity is used to test the statistical
8 significance of the difference between the study arms of each PRO item

9 Subgroup analyses will be performed stratified by type of ADT or antiandrogen therapy initially
10 selected; GnRH agonists/antagonists, antiandrogen, orchiectomy, or other. Men who start with
11 antiandrogen therapy often change to GnRH agonists/antagonists or orchiectomy when PSA increases
12 during ADT. This is allowed and PSA recurrence during antiandrogen therapy is not considered as
13 disease progression as serum testosterone needs to be at castrate level as well for meeting the primary
14 endpoint.

15 Another subgroup analysis will be stratified by whether or not the participants have received local
16 therapy (radiation or surgery) for prostate cancer in addition to ADT and by type of additional therapy
17 participant has received; docetaxel, abiraterone, enzalutamide, or apalutamide at hormone-sensitive
18 stage in addition to ADT.

19 All analyses will include only participants with available data, imputations will not be used. Detailed
20 statistical analysis plan is published before final data analysis. All analyses are performed using SPSS,
21 Stata and R statistical softwares.

22 **Quality control**

23 The study steering committee includes investigators from each participating recruitment center. The
24 steering committee will meet twice a year to oversee trial progression of the recruitment, integrity of
25 collected data and discuss possible protocol amendments.

26 External trained study monitors independent from the study sponsors ensure the data quality and good
27 clinical practice by making regular yearly check-up visits to participating study centers. This will be
28 separately arranged in each participating country.

1 **Reporting and registering of adverse effects**

2 The participants are advised to contact the researchers in case of suspected adverse effect related to
3 the study drug. If the side-effects are intolerable the study drug will be discontinued. In uncertain
4 cases serum levels of creatine kinase (U/l), alanine aminotransferase (U/l) and creatinine ($\mu\text{mol/l}$)
5 are checked to see if any of these have changed considerably compared to the baseline. If the
6 laboratory tests are not normal, or if the participant or the attending physician finds the side-effects
7 alarming the study drug will be discontinued. Study database records specifically most common
8 adverse effects muscular pain, elevated fasting blood glucose ($> 6,1 \text{ mmol/l}$) and elevated serum
9 creatine kinase ($>280 \text{ U/l}$), even when they do not lead to discontinuation of the study drug.

10 Trial database, REDCap, includes separate question for serious adverse effects as evaluated by
11 CTCAE criteria, version 5.0. If serious side-effects are reported, REDCap asks to fulfill separate
12 query where detailed description of the adverse effect is given according to CTCAE criteria. Study
13 sponsor and coordinator will be automatically notified via e-mail if serious adverse effect is reported
14 in the database. All serious adverse effect that threatens life or health are reported to national authority
15 (FIMEA in Finland) within 7 days of detection. If a life-threatening adverse effect is suspected
16 blinding will be lifted for the participant in case to see whether he has received atorvastatin or placebo.
17 Unexpected adverse effects will be reported to national authority within 15 days of detection.

18 **Patients and public involvement**

19 In the design phase of the trial, primary investigator presented the study protocol in numerous public
20 events, including patient advocacy group meetings, giving opportunity for the audience to give
21 feedback and suggestions how to improve the study. Patient advocacy organizations of prostate
22 cancer patients are actively involved in finding subjects for the study through announcements in their
23 journals and by allowing investigators frequently promote the study in their meetings. Study results
24 will be also reported in patient organization journals and social media sites for maximum visibility
25 and distribution of trial outcomes.

26 **Ethics and dissemination**

27 This study is approved by the regional ethics committee of Pirkanmaa Hospital District, Science
28 center, Tampere, Finland (R18065M). All participants read and sign informed consent form before
29 study entry. The results of this study will be published in international peer reviewed journals.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The trial is ethical for the following reasons 1); The study aims to improve treatment of metastatic prostate cancer, which is the second most common cause of cancer death in Western countries, 2); the potential scientific and societal benefits from the project are substantial. If the study hypothesis proves to be right, it will provide an entirely new way to prevent and/or delay progression of metastatic prostate cancer with atorvastatin, a drug that is cheap, well-tolerated, and with established cardiovascular benefits, 3); the study drug (atorvastatin) is known to be well-tolerated and it is currently widely used in management of hypercholesterolemia and cardiovascular disease. The adverse effects caused by the drug are usually mild and transient after stopping the study drug, and 4); randomized, placebo-controlled design ensures the study will produce highest quality evidence that will change prostate cancer treatment guidelines if the hypothesis proves to be right.

After publication of results for the primary endpoints, anonymized summary metadata and statistical code will be made openly available. The data will not include any information that could make it possible to identify a given participant.

References

1. Finnish cancer registry statistics: <http://stats.cancerregistry.fi/stats/eng/veng0003m0.html>
2. Mäklin S, Rissanen P. Cancer expenses in Finland: <http://www.cancer.fi/@Bin/47734/Syöpien+aiheuttamat+kustannukset.pdf>
3. Ross RW Xie W, Regan MM, Pomerantz M, *et al.* Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. *Cancer* 2008;**112**:1247-53. doi: 10.1002/cncr.23304.
4. Botrel TE, Clark O, Lima Pompeo AC, *et al.* Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. *PLoS One* 2016;**11**:e0157660. doi: 10.1371/journal.pone.0157660.
5. Sweeney CJ, Chen YH, Carducci M, *et al.* Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. *N Engl J Med* 2015;**373**:737-46. doi: 10.1056/NEJMoa1503747
6. Seo WI, Kang PM, Kim TH, *et al.* Primary androgen deprivation therapy for prostate cancer in koreans: a retrospective multicenter study. *World J Mens Health*. 2014;**32**(3):159-66.

- 1
2
3 1 7. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM. Intermittent
4 2 hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. *BJU Int*
5 3 2012;**110**:1262-9. doi: 10.1111/j.1464-410X.2012.11120.x.
- 6 3
7 4
8 4 8. Arthur R, Møller H, Garmo H, *et al.* Association between baseline serum glucose,
9 5 triglycerides and total cholesterol, and prostate cancer risk categories. *Cancer Med*
10 6 2016;**5**:1307-18. doi: 10.1002/cam4.665
- 11 6
12 7
13 7 9. Murtola TJ, Syväälä H, Pennanen P, *et al.* Comparative effects of high and low-dose
14 8 simvastatin on prostate epithelial cells: the role of LDL. *Eur J Pharmacol* 2011;**673**:96-100.
15 9 doi: 10.1016/j.ejphar.2011.10.022.
- 16 9
17 10
18 10 10. Murtola TJ, Syväälä H, Pennanen P, *et al.* The importance of LDL and cholesterol metabolism
19 11 for prostate epithelial cell growth. *PLoS One* 2012;**7**:e39445. doi:
20 12 10.1371/journal.pone.0039445.
- 21 12
22 13
23 13 11. Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor
24 14 microenvironment. *Trends Cell Biol* 2014;**24**:472-8. doi: 10.1016/j.tcb.2014.06.001.
- 25 14
26 15
27 15 12. Herber DL, Cao W, Nefedova Y *et al.* Lipid accumulation and dendritic cell dysfunction in
28 16 cancer. *Nat Med* 2010;**16**:880-6. doi: 10.1038/nm.2172
- 29 16
30 17
31 17 13. Han W, Gao S, Barrett D, *et al.* Reactivation of androgen receptor-regulated lipid biosynthesis
32 18 drives the progression of castration-resistant prostate cancer. *Oncogene* 2018;**37**:710-21. doi:
33 19 10.1038/onc.2017.385.
- 34 19
35 20
36 20 14. Raval AD, Thakker D, Negi H, *et al.* Association between statins and clinical outcomes
37 21 among men with prostate cancer: a systematic review and meta-analysis. *Prostate Cancer*
38 22 *Prostatic Dis* 2016;**19**:222. doi: 10.1038/pcan.2016.3
- 39 22
40 23
41 23 15. Barfeld SJ, Itkonen HM, Urbanucci A, *et al.* Androgen-regulated metabolism and
42 24 biosynthesis in prostate cancer. *Endocr Relat Cancer* 2014;**21**:T57-66. doi: 10.1530/ERC-13-
43 24 0515.
- 44 25
45 26
46 26 16. Dambal S, Howard LE, Allott EH, *et al.* Serum Lipids prior to Starting Androgen Deprivation
47 27 Therapy and Risk of Castration Resistant Prostate Cancer and Metastasis: Results from the
48 28 SEARCH Database. *J Urol* 2020;**203**:120-7. doi: 10.1097/JU.0000000000000494
- 49 28
50 29
51 29 17. Van Rompay MI, Solomon KR, Nickel JC, *et al.* Prostate cancer incidence and mortality
52 30 among men using statins and non-statin lipid-lowering medications. *Eur J Cancer*
53 31 2019;**112**:118-26. doi: 10.1016/j.ejca.2018.11.033.
- 54 31
55 32
56 32 18. Kumar A, Riviere P, Luterstein E, *et al.* Associations among statins, preventive care, and
57 33 prostate cancer mortality. *Prostate Cancer Prostatic Dis* 2020. doi: 10.1038/s41391-020-
58 33 0207-5
- 59 33
60 34

- 1
2
3 1 19. Murai T. Cholesterol lowering: role in cancer prevention and treatment. *Biol Chem*
4 2015;**396**:1-11. doi: 10.1515/hsz-2014-0194.
5 2
6 3
7 3 20. Garcia-Ruiz C, Morales A, Fernandez-Checa JC. Statins and protein prenylation in cancer
8 4 cell biology and therapy. *Anticancer Agents Med Chem* 2012;**12**:303-15. doi:
9 10.2174/187152012800228715
10 5
11 6
12 6 21. Armandari I, Hamid AR, Verhaegh G, *et al.* Intratumoral steroidogenesis in castration-
13 7 resistant prostate cancer: a target for therapy. *Prostate Int* 2014;**2**:105-13. doi:
14 10.12954/PI.14063.
15 8
16 9
17 9 22. Mokarram P, Alizadeh J, Razban V, *et al.* Interconnection of Estrogen/Testosterone
18 10 Metabolism and Mevalonate Pathway in Breast and Prostate Cancers. *Curr Mol Pharmacol*
19 2017;**10**:86-114. doi: 10.2174/1874467209666160112125631.
20 11
21 12
22 12 23. Harshman LC, Wang X, Nakabayashi M, *et al.* Statin use at the time of initiation of androgen
23 13 deprivation therapy and time to progression in patients with hormone-sensitive prostate
24 14 cancer. *JAMA Oncol* 2015;**1**:495-504. doi: 10.1001/jamaoncol.2015.0829.
25 15
26 16
27 15 24. Jung J, Lee C, Lee C, *et al.* Effects of statin use on the response duration to androgen
28 16 deprivation therapy in metastatic prostate cancer. *Korean J Urol* 2015;**56**:630-6. doi:
29 10.4111/kju.2015.56.9.630.
30 17
31 18
32 18 25. Syvälä H, Pennanen P, Bläuer M, *et al.* Additive inhibitory effects of simvastatin and
33 19 enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer cells. *Biochem*
34 20 *Biophys Res Commun* 2016;**481**:46-50. doi: 10.1016/j.bbrc.2016.11.021
35 21
36 20 26. Yang H, Pang L, Hu X, *et al.* The effect of statins on advanced prostate cancer patients with
37 21 androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-
38 22 analysis. *J Clin Pharm Ther* 2020;**45**:488-95. doi: 10.1111/jcpt.13092
39 23
40 24
41 24 27. Lv HL, Jin DM, Liu M, *et al.* Long-term efficacy and safety of statin treatment beyond six
42 25 years: a meta-analysis of randomized controlled trials with extended follow-up. *Pharmacol*
43 26 *Res* 2014;**81**:64-73. doi: 10.1016/j.phrs.2014.02.006.
44 27
45 28
46 27 28. Murtola T, Riikonen J, Syvälä H, *et al.* Atorvastatin Versus Placebo for Prostate Cancer
47 28 Before Radical Prostatectomy-A Randomized, Double-blind, Placebo-controlled Clinical
48 29 Trial. *Eur Urol* 2018;**74**:697-701. doi: 10.1016/j.eururo.2018.06.037.
49 30
50 30 29. Longo J, Hamilton RJ, Masoomian M, *et al.* A pilot window-of-opportunity study of
51 31 preoperative fluvastatin in localized prostate cancer. *Prostate Cancer Prostatic Dis* 2020
52 32 ;**23**:630-37. doi: 10.1038/s41391-020-0221-7
53
54
55
56
57
58
59
60

- 1
2
3 1 30. Hamilton RJ, Ding K, Crook JM, *et al.* The Association Between Statin Use and Outcomes
4 2 in Patients Initiating Androgen Deprivation Therapy. *Eur Urol* 2020 (article in press)
5 3 <https://doi.org/10.1016/j.eururo.2020.12.031>
6 4
7 31. Harris PA, Taylor R, Thielke R, *et al.* Research electronic data capture (REDCap) – A
8 5 metadata-driven methodology and workflow process for providing translational research
9 6 informatics support. *J Biomed Inform* 2009;**42**:377-81. doi: 10.1016/j.jbi.2008.08.010
10 7
11 32. Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: Building an international
12 8 community of software partners. *J Biomed Inform* 2019;**95**:103208. doi:
13 9 10.1016/j.jbi.2019.103208.
14 10
15 33. WHOQOL-BREF, The World Health Organization Quality of Life, THL
16 11
17 34. Mateo J, Boysen G, Barbieri CE, *et al.* DNA repair in prostate cancer: biology and clinical
18 12 implications. *Eur Urol* 2017;**71**:417-25. doi: 10.1016/j.eururo.2016.08.037
19 13
20 35. Xu J, Qiu Y. Role of androgen receptor splice variants in prostate cancer metastasis. *Asian J*
21 14 *Urol* 2016;**3**:177-84. doi: 10.1016/j.ajur.2016.08.003.
22 15
23 36. Le QT, Courter D. Clinical biomarkers for hypoxia targeting. *Cancer Metastasis Rev*
24 16 2008;**27**:351-62. doi: 10.1007/s10555-008-9144-9
25 17
26 37. Stieb S, Eleftheriou A, Warnock G, *et al.* Longitudinal PET imaging of tumor hypoxia during
27 18 the course of radiotherapy. *Eur J Nucl Med Mol Imaging* 2018;**45**:2201-17.doi:
28 19 10.1007/s00259-018-4116-y
29 20
30 38. Hunt SJ, Seraj SM, Alavi A. PET Assessment of Immune Effects from Interventional
31 21 Oncology Procedures. *PET Clin* 2019;**14**:477-85. doi: 10.1016/j.cpet.2019.06.007.
32
33
34
35
36
37
38
39

40 22 **Authors' contributions:** T.J.M. is the primarily investigator of this study and designed and planned
41 23 the study with the help from all other authors. J.R., T.P., O.E., P.B., H.S., A.K., T.L.J.T., M.F., P.Ø.,
42 24 A.R., T.M., A.Sa., H.R., S.L., and T.J.M. will be conducting the study at the study centers. M.H. and
43 25 P.V.R. planned and will conduct the statistical analysis of the study. T.L helped to plan and
44 26 collaborate in analysis of lipidomic profile. A.Si is coordinator of the trial. A.Si. and T.J.M. wrote
45 27 the first draft of the manuscript. All other authors further contributed to manuscript preparation and
46 28 accepted the final version of the manuscript.
47
48
49
50
51
52

53 29 **Funding:** This study is supported by grants from Finnish Cancer Foundation (grant numbers 024194
54 30 and 3122800563 (TJM) and 16112016 (TL)), Nordic Cancer Union (grant number MS793 (TJM)),
55 31 Päivikki and Sakari Sohlberg Foundation (grant number 31228005901 (AS)), competitive research
56 32 grant of Pirkanmaa hospital district (grant number 9X032 (TJM) and grant X51001 (TL)), and the
57 33 Academy of Finland (grants numbers 322098 (TL), and 3121330724 (TJM)).
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Disclaimer: None of the funders has a role in the design, management, analysis or interpretation of data, or writing and publication of results.

Competing interests: Peter Østergren: honorarium as speaker from Ipsen A/S, Ferring Pharmaceuticals, and Astellas Pharma. Mikkel Fode: consultant fees and honorarium as speaker from Astellas and Ferring. Hanna Ronkainen: consultant fees from Bayer AB and honorarium as speaker from Sanofi. Teemu J Murtola: Consultant fees from Astellas, Janssen, speaker's honorarium from Astellas, Janssen and Sanofi, participation in scientific meetings at the expense of Ferring, Pfizer, and Sanofi, stockholder for Arocell AB. Peter Boström: consultant fees from Astellas Pharma. All other authors: No competing interests to declare.

Data sharing: There are no additional unpublished data at this point of this study.

Captions to Figure and Tables:

Figure 1. Study flow with inclusion and exclusion criteria.

Figure 2. Sample size estimation with power 0.8 as a function of hazard ratio. Calculation was made based on study by Harshman et al.²³

Table 1. Study setting of Impact of atorvastatin on prostate cancer after initiation of androgen deprivation therapy -clinical trial

Table 2. Study flow and timing of the laboratory and blood sample collection

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only


18 Table 1. Study setting of Impact of atorvastatin on prostate cancer after initiation of androgen
19 deprivation therapy -clinical trial.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Study settings	
Primary registry and trial identifying number	Clinicaltrials.gov NCT04026230
Date of registration in primary registry	July 19, 2019
Secondary identifying numbers	Eudra-CT: 2016-004774-17, Protocol code: ESTO2
Source(s) of monetary or material support	Tampere University Hospital, Finland
Primary sponsor	Tampere University Hospital, Finland
Secondary sponsor(s)	Helsinki University Hospital, Turku University Hospital, Central Finland Central Hospital, Kuopio University Hospital, Oulu University Hospital, Finland, Herlev Hospital, Denmark, University Hospital Tartu, Estonia, Vestfold Hospital Trust, Tønsberg, Norway
Contact for public queries	Tampere University Hospital, Teemu Murtola, MD, PhD
Contact for scientific queries	Tampere University Hospital, Teemu Murtola, MD, PhD
Public title	Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy
Scientific title	Impact of atorvastatin on prostate cancer progression after initiation of androgen deprivation therapy – lipid metabolism as a novel biomarker to predict prostate cancer progression – phase 3, double-blind randomized clinical trial FinnProstata XV
Countries of recruitment	Finland, Denmark, Estonia, Norway
Health condition studied	Metastatic or recurrent prostate cancer
Intervention	Active comparator: Capsules of atorvastatin 80 mg, Placebo comparator: Similar capsules as in the atorvastatin arm, but without the active ingredient
Key inclusion and exclusion criteria	Inclusion criteria: Histopathologically confirmed metastatic adenocarcinoma of the prostate for which androgen deprivation or antiandrogen therapy is initiated no longer than 3 months before the primary treatment Willingness to participate and signing of informed consent Exclusion criteria: Statin use at the time of recruitment or within 3 months of it, Previous adverse effects during statin therapy, family history of hypercholesterolemia or very high total cholesterol, clinically significant renal or liver insufficiency, use of drugs that may interact with statins
Sexes eligible for study:	Male
Accepts healthy volunteers	No
Study type	Interventional, Allocation: randomized, Intervention model: parallel assignment with 1:1 allocation ratio, Masking: double blind (subject, caregiver, investigator, outcomes assessor), Primary purpose: prevention, Phase III
Date of first enrolment	July 2019
Target sample size	400
Recruitment status	Recruiting
Primary outcome(s)	Castration resistance
Key secondary outcomes	Lipid levels, Prostate cancer mortality and overall survival, Circulating PSA, PSA doubling time, Time to next antiandrogen therapy


Table 2. Study flow and timing of the laboratory and blood sample collection.

TIMEPOINT	Enrollment	Allocation	Follow-up			
			0 6m	12m	18m	24m
ENROLLMENT:						
Eligibility screen	x					
Informed consent	x					
Allocation		x				
INTERVENTIONS:+						
Atorvastatin			x	x	x	x
Placebo			x	x	x	x
ASSESMENTS:						
Serum PSA (ng/ml)	x		x	x	x	x
Alkaline phosphatase (U/l)	x		x	x	x	x
Creatinine (µmol/l)	x		x	x	x	x
Serum creatine kinase (U/l)	x		x	x	x	x
Alanine aminotransferase (U/l)	x		x	x	x	x
Fasting blood glucose (mmol/l)	x		x	x	x	x
Lipid levels (total cholesterol, LDL, HDL, and triglycerides) (mmol/l)	x		x	x	x	x
Cell free DNA (subgroup)^	x					
QoL	x			x		x
m=month, QoL=quality of life, PSA=prostate-specific antigen						
*follow-up until disease recurrence, death, or max. 10 years						
+ allocation 1:1 to have either 80 mg atorvastatin or placebo daily						
^Cell free DNA is measured before allocation and after occurrence of castration resistance.						



Study flow with inclusion and exclusion criteria.

1184x868mm (72 x 72 DPI)

Sample size as a function of HR, power = 0.8

Sample size estimation with power 0.8 as a function of hazard ratio. Calculation was made based on study by Harshman et al.²³

599x549mm (72 x 72 DPI)



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	_____ 1 _____
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	_____ 2 _____
	2b	All items from the World Health Organization Trial Registration Data Set	_____
Protocol version	3	Date and version identifier	_____ 2 _____
Funding	4	Sources and types of financial, material, and other support	_____ 14 _____
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	_____ 1 _____
	5b	Name and contact information for the trial sponsor	_____ 1 _____
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	_____ 14 _____
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	_____ 10 _____

1 **Introduction**

2

3 Background and rationale 6a Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention ___ 3-4 ___

4

5

6 6b Explanation for choice of comparators ___ 3-4 ___

7

8 Objectives 7 Specific objectives or hypotheses ___ 5 ___

9

10 Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) ___ 5-6 ___

11

12

13

14 **Methods: Participants, interventions, and outcomes**

15

16 Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained ___ 5-6 ___

17

18

19 Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) ___ 6 ___

20

21

22 Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be administered ___ 7-8 ___

23

24

25 11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) ___ 6 ___

26

27

28 11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) ___ 7-8 ___

29

30

31 11d Relevant concomitant care and interventions that are permitted or prohibited during the trial ___ 8 ___

32

33

34 Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended ___ 6-7 ___

35

36

37

38

39

40 Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) ___ 7-8, Table 2 ___

41

42

43

44

45

46

1 Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including _____ 8-9 _____
 2 clinical and statistical assumptions supporting any sample size calculations

3
 4 Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size _____ 8-9 _____
 5

6 **Methods: Assignment of interventions (for controlled trials)**

7
 8 Allocation:

9
 10 Sequence 16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any _____ 7 _____
 11 generation factors for stratification. To reduce predictability of a random sequence, details of any planned restriction
 12 (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants
 13 or assign interventions
 14
 15

16 Allocation 16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, _____ 7 _____
 17 concealment opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned
 18 mechanism
 19

20 Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to _____ 7 _____
 21 interventions
 22
 23

24 Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome _____ 7 _____
 25 assessors, data analysts), and how
 26

27 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's _____ 7 _____
 28 allocated intervention during the trial
 29
 30

31 **Methods: Data collection, management, and analysis**

32
 33 Data collection 18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related _____ 7-8 _____
 34 methods processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of
 35 study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known.
 36 Reference to where data collection forms can be found, if not in the protocol
 37

38
 39 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be _____ 6 _____
 40 collected for participants who discontinue or deviate from intervention protocols
 41
 42

1	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	_____5_____
2				
3				
4				
5	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	__9-10_____
6				
7				
8		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	__9-10_____
9				
10		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	_____10_____
11				
12				
13				
14	Methods: Monitoring			
15				
16	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	_____10_____
17				
18				
19				
20				
21				
22		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	_____6, 11_____
23				
24				
25	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	_____11_____
26				
27				
28	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	_____10_____
29				
30				
31				
32	Ethics and dissemination			
33				
34	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	_____10_____
35				
36				
37	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	_____10_____
38				
39				
40				
41				
42				
43				
44				
45				
46				

1	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	_____7_____
2				
3				
4		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	_____
5				
6				
7	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	_____5_____
8				
9				
10	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	_____15_____
11				
12				
13	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	_____5_____
14				
15				
16	Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	_____
17				
18				
19				
20	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	_____10_____
21				
22				
23				
24		31b	Authorship eligibility guidelines and any intended use of professional writers	_____
25				
26		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	_____
27				
28				
29	Appendices			
30				
31	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	_____
32				
33				
34	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	_____
35				
36				

37 *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items.
 38 Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons
 39 "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.
 40